MedTrace Logo

CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk

NCT01050400 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 330

Last updated 2017-08-28

No results posted yet for this study

Summary

The purpose of this study is to determine if non-invasive salivary genetic screening of breastfeeding mothers taking codeine will allow for the successful identification of mother-infant pairs susceptible to adverse events and to prevent these adverse events by personalizing their medication to their genetics.

Conditions

  • Cytochrome P450 2D6 Ultra-rapid Metabolism

Interventions

GENETIC

Cytochrome P450 2D6 (CYP2D6) genetic screening.

Genetic screening for cytochrome P450 2D6 (CYP2D6) polymorphism will be conducted on genetic information obtained from non-invasive salivary samples.

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Gideon Koren, MD · Western University, Canada

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-24
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01050400 on ClinicalTrials.gov